PAVmed (PAVM) Stock Price

PAVmed Price

NASDAQ·CLOSED
3.82
​
Market closed

Revenue at PAVmed has contracted by 38.6% per year over the past 4 years to 71,000.00 USD. PAVmed's net margin stands at 564.8%, up from -10,069.4% several years earlier. Analysts set a median price target of 10.71 USD, implying 180.7% above the current price. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.

PAVmed stock price

Access this data via the Eulerpool API

PAVmed business model & stock analysis

PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. The company is headquartered in New York City, New York and currently employs 15 full-time employees. The company went IPO on 2016-07-27. The firm's products include PortIO, Caldus, CarpX, NextCath, DisappEAR and NextFlo. PortIO is an implantable vascular access device, which does not require accessing the central venous system and does not have an indwelling intravascular component. CarpX is a percutaneous device to treat carpal tunnel syndrome. NextCath is a self-anchoring catheter, which does not require suturing, traditional anchoring techniques or add-on catheter securement devices. The firm's DisappEAR is an Antibiotic-eluting Resorbable Ear Tubes. The firm is engaged in developing and commercializing antibiotic-eluting resorbable ear tubes based on an aqueous silk technology conceived and developed at these institutions. The firm is engaged in developing disposable infusion system with variable flow resistors. Caldus is a disposable tissue ablation device.

Frequently asked questions about PAVmed

Analysts currently set an average price target of 10.71 USD for the PAVmed stock (median: 10.71 USD), implying +296.7 % versus the latest price. The consensus is based on 8 analyst ratings.

8 analysts currently rate the PAVmed stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect PAVmed to generate revenue of 232,500.00 USD and earnings per share of -3.01 USD.

Converted at the current exchange rate, the PAVmed share trades at 3.39 EUR (3.82 USD).

The PAVmed share (PAVM) is listed on 3 stock exchanges, including: NASDAQ (PAVMZ), Frankfurt (1P5.F), Düsseldorf (1P5.DU).

The expected revenue of PAVmed is 232,500.00 USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of PAVmed is -2.33 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of PAVmed is currently -1.27. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the PAVmed stock.

The price-to-sales ratio (P/S) of PAVmed is currently 12.69. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the PAVmed stock.

The Eulerpool Quality Score for PAVmed is 3/10.

The ISIN of PAVmed is US70387R5028. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of PAVmed is A2AQDJ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of PAVmed is PAVM. The ticker symbol is used to trade PAVmed shares on the stock exchange.

Fair ValueTerminal
3.66 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
1,731.71 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website pavm.com
Currency
USD
Initial public offering
Jul 27, 2016
ISIN
US70387R5028
Cusip
70387R106
Sedol
BDC6H83
Market capitalization
3.82 M USDMicro Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee 2026
-1.27
P/Ee 2027
-1.24
P/Se
12.69
EV/EBIT
—
P/B Ratio
0.11
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
0.85 %
Gross Margin
-354.93 %
EBIT Margin
-30,712.67 %
Net Margin
564.79 %
EPS (Earnings Per Share)
0.52 USD
Net Debt / EBIT
-0.54
Debt/Equity
0.39
Last updated Oct 3, 2026, 1:31 AM

PAVmed Ticker

DÜSSELDORF · 1P5.DUFRANKFURT · 1P5.FNASDAQ · PAVMZ

All fundamentals and in-depth analysis of PAVmed

Our stock analysis for PAVmed stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PAVmed. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.